依达拉奉右莰醇治疗缺血性脑卒中的研究进展OA

Ischemic stroke is a common type of cerebrovascular disease that can lead to advanced cognitive and motor deficits and even death.The treatment of ischemic stroke mainly includes early thrombolysis and neuroprotection.However,the clinical efficacy of neuroprotective agents remains to be verified,and most neuroprotective agents have not yet received useful evidence.Edaravone Dexborneol(ED),a new dual-target neuroprotective agent,can inhibit the expression of inducible nitric oxide synthase(iNOS)and tumor necrosis factor-α(TNF-α),reduce the level of peroxynitrite anion(ONOO-),and improve the symptoms of nerve injury,dysfunction,and activity disorder caused by ischemic stroke.This article will review the mechanism of ED and its application development,and prospect the clinical application of ED,so as to provide guidance for subsequent medication.